Navigating key news stories in pharma

Subscribe

Featured Stories

Featured
Integrating Sustainability into the Pharma Value Chain
Strategy
Integrating Sustainability into the Pharma Value Chain
Strategy

As the industry pivots toward eco-design and green procurement, the whole value chain must align to bridge the gap between environmental targets and manufacturing reality.

Read More →
Strategy
News
ten23 health Validates West Synchrony S1 Prefillable Syringe Platform
Strategy
ten23 health Validates West Synchrony S1 Prefillable Syringe Platform
Strategy

Following the global launch of the Synchrony S1 PFS system, ten23 health has completed robustness testing to ensure the platform is ready for clients navigating the complexities of drug-device regulations.

Read More →
Strategy
Bayer Strengthens Ophthalmology Pipeline with Perfuse Therapeutics Acquisition
Dealmaking
Bayer Strengthens Ophthalmology Pipeline with Perfuse Therapeutics Acquisition
Dealmaking

By securing the rights to a Phase II dissolvable implant for glaucoma and diabetic retinopathy, targeting the underlying vascular causes of vision loss, Bayer is positioning itself at the forefront of long-acting ocular drug delivery.

Read More →
Dealmaking
Future-Proofing the Small-Molecule Pipeline with Spray Drying
Strategy
Future-Proofing the Small-Molecule Pipeline with Spray Drying
Strategy

With industry reaching the limits of traditional formulation techniques, to overcome solubility and bioavailability challenges, spray-drying is increasingly emerging as a primary development pillar.

Read More →
Strategy

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
PCI Pharma Services Unveils Major Expansion
PCI Pharma Services Unveils Major Expansion

Philadelphia-based CDMO, PCI Pharma Services, has committed to substantial investments in sterile fill/finish and drug-device combination assembly across its global operations.

A Modular Revolution in Biomanufacturing
A Modular Revolution in Biomanufacturing

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

ten23 health Opens New Office in Tokyo
ten23 health Opens New Office in Tokyo

The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies across the region.

Vetter Advances New U.S. Site and Upgrades Austrian Facility
Vetter Advances New U.S. Site and Upgrades Austrian Facility

In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.

Dealmaking

Featured
Bayer Strengthens Ophthalmology Pipeline with Perfuse Therapeutics Acquisition
Bayer Strengthens Ophthalmology Pipeline with Perfuse Therapeutics Acquisition

By securing the rights to a Phase II dissolvable implant for glaucoma and diabetic retinopathy, targeting the underlying vascular causes of vision loss, Bayer is positioning itself at the forefront of long-acting ocular drug delivery.

Sun Pharma Agrees All-Cash Acquisition of Organon
Sun Pharma Agrees All-Cash Acquisition of Organon

The acquisition is expected to create a global powerhouse in women’s health, biosimilars and branded generics with operations in 150 countries, and is set to close in early 2027 pending approvals.

Alcami Establishes Transatlantic Footprint with Tjoapack Acquisition
Alcami Establishes Transatlantic Footprint with Tjoapack Acquisition

With this definitive acquisition agreement, the CDMO will expand its presence on the global market with its first European location and will enable greater customer support.

Circio and Acuitas Initiate Technology Evaluation Agreement
Circio and Acuitas Initiate Technology Evaluation Agreement

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

Strategy

Featured
ten23 health Validates West Synchrony S1 Prefillable Syringe Platform
ten23 health Validates West Synchrony S1 Prefillable Syringe Platform

Following the global launch of the Synchrony S1 PFS system, ten23 health has completed robustness testing to ensure the platform is ready for clients navigating the complexities of drug-device regulations.

Future-Proofing the Small-Molecule Pipeline with Spray Drying
Future-Proofing the Small-Molecule Pipeline with Spray Drying

With industry reaching the limits of traditional formulation techniques, to overcome solubility and bioavailability challenges, spray-drying is increasingly emerging as a primary development pillar.

Integrating Sustainability into the Pharma Value Chain
Integrating Sustainability into the Pharma Value Chain

As the industry pivots toward eco-design and green procurement, the whole value chain must align to bridge the gap between environmental targets and manufacturing reality.

Figuring Out the New Economics of Niche
Figuring Out the New Economics of Niche

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

Future Biopharma

Featured
Tipping the Scales: The Benefits of Continuous Bioprocessing
Tipping the Scales: The Benefits of Continuous Bioprocessing

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.

A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026
A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026

Driven by regulatory evolution and a commitment to sustainability, the excipients’ sector is reinforcing its position as a sophisticated and credible stakeholder in the modern pharmaceutical supply chain.

Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Transforming the Treatment Landscape with Tailored Therapies
Transforming the Treatment Landscape with Tailored Therapies

Patient outcomes are transforming, thanks to innovative, curative, tailored therapies; however, industry needs to address a few pressing issues to ensure the huge promise of these drugs can be achieved.

Regulatory

Featured
First Targeted CSU Therapy for Children Gets Nod from European Commission
First Targeted CSU Therapy for Children Gets Nod from European Commission

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan

The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.

CBER Issues RTF for Moderna’s Investigational Flu Shot
CBER Issues RTF for Moderna’s Investigational Flu Shot

According to Moderna, the reasoning for the refusal to review the BLA by the regulatory authority is inconsistent with previous feedback, leading the company to request a Type A meeting.

Upcoming Events

Featured
interpack 2026

interpack is the world's leading trade fair for packaging and processing solutions. It takes place every three years in Düsseldorf and is an indispensable meeting place for everyone involved in the packaging, food, pharmaceutical, and related industries.

TIDES USA 2026

TIDES USA is North America’s annual, leading conference on oligonucleotide, peptide, mRNA, genome editing, and drug delivery therapeutics, covering discovery, development, and commercialization.

ASGCT Annual Meeting 2026

As the largest and most comprehensive cell and gene therapy event, the Annual Meeting offers unique opportunities to explore the latest scientific research, stay abreast of new technologies, and forge career-advancing connections.